CatSci’s 2022 So Far…

CatSci’s 2022 So Far…

CatSci has had an incredibly exciting start to 2022. As April draws to an end, we wanted to round up just some of the exciting developments that this year has already brought.

As we pursue our mission to get life-saving therapeutics to patients all over the globe, we are continually expanding our capabilities and offerings.

The Queen’s Awards For Enterprise: International Trade 2022

We are delighted to announce that we have won the coveted Queen’s Award for Enterprise: International Trade 2022. This is a monumental achievement for CatSci. The Queen’s Awards for Enterprise are one of the most prestigious business awards in the UK, and we are honoured that our hard work and dedication to medicines development has been recognised in this manner. The accolade reflects CatSci’s outstanding innovation and cutting-edge scientific expertise, and solidifies our position as a dynamic, agile and world-class innovation partner for global pharmaceutical companies.
Find out more.

The Bionow Export of the Year Award

We have also won the Bionow Awards Export of the Year Award. This prestigious award is another huge achievement for CatSci. As a UK-based company in the competitive and dynamic pharmaceutical marketplace we are proud to be putting Wales on the pharmaceutical industry’s international map, and showcasing ourselves as a centre for excellence and top-quality science for our customers across the globe.
Find out more.

New Appointments

We have been focused on expanding our team to offer more and better to our customers. Along with the addition of many new scientists, we have appointed new senior roles to enhance our offerings, led by experts in the field.

Dr Gary Parsons
Director of Pharmaceutical Development

Dr Gary Parsons has joined the CatSci team as our Director of Pharmaceutical Development. Gary brings with him a breadth of expertise and experience, after coming from his role as Respiratory Technical Director at GSK. He has notable expertise in inhaled product development, having worked across all phases of development, from lead optimisation to initial commercial supply in support of the creation of GSK’s Ellipta portfolio of inhaled medicines. He will be influential in integrating our API material science capabilities into dosage form design to offer our customers better flexibility and optionality early on, as well as delivering his own passion and drive for innovative pharmaceutical development. His experience and expertise make him the perfect fit for our ambitious plans for further growth.
Find out more.

Dr Robert Crook
Director of Chemical Development

In May, Dr Robert Crook will be joining the team as our new Director of Chemical Development. Rob will be bringing over 28 years of pharma expertise across the CMC landscape; has held several Senior Roles withing Pfizer, most recently leading the Sandwich API Development Laboratories. Rob will be driving forward our chemical development offering, and working closely with our formulation, measurement and material science functions to offer even more integrated and bespoke solutions to our customers, allowing us to provide a more holistic approach to medicines development.
Find out more.

Jenn Clark
Head of Account Management

Jenn Clark will be joining us as our Head of Account Management. This role further ensures that our capabilities are always aligned to the needs and expectations of our customers, now and in the future. Jenn will act as a key communicator to bridge any gaps between us and our customers; she will leverage the internal talent and capabilities of CatSci with our customers’ high expectations so we continue to deliver value-adding outcomes to our customers.
Find out more.

A Medicine is More Than a Molecule
24th May 2022

We will be hosting a free virtual symposium entitled “A Medicine is More Than a Molecule” on Tuesday 24th May at 16:00 (BST)/ 8:00am (PDT)/ 11:00am (EDT)/ 17:00 (CET) on LabLinks. Hosted by Dr Robert Dennehy (our Director of Material Sciences) and Dr Gary Parsons (our Director of Pharmaceutical Development), the event will explore the crucial role of material science in product design. Our experts will discuss the cruciality of understanding the physical solid-state properties of your API process to improve the probability of success and the security of supply.
Register here.

Introducing SmartPath

Another exciting development that we will be formally introducing on the “A Medicine is More Than a Molecule” symposium is SmartPath. SmartPath is your tailored API Risk Assessor that will help you mitigate the risks of your API process in order to achieve success. There will be much more to be announced on SmartPath at the event, so watch this space and make sure to register to the event to find out more.
Register here.

Expansion into Japan

In line with our continued evolution, we have now expanded into the Japanese market. This is a pivotal step in our global growth strategy. We have launched our website for our Japanese customers, so that with our support, they can continue to meet the healthcare needs of the world. This key expansion will support our innovative and ambitious export strategy as we continue our global journey.
Find out more.

CPhI North America

We will also be attending the CPhI North America Event on 17th – 19th May 2022. Our Head of Business Development in North America, Dr Jas Douville, will be attending the in-person event. He will be available to discuss CatSci’s offerings and capabilities, so please do get in touch with Jas here if you would like to arrange a meeting.